Bonus BioGroup
Bonus BioGroup (TASE: BONS) is a biotechnology company applying a proprietary, innovative, tissue engineering technology to produce cell-based therapies.
Recent News
-
Bonus BioGroup Submits Outstanding Phase-II Trial Results for MesenCure, a Treatment for Severe COVID-19, to the Israeli Ministry of Health
Tel Aviv, Israel--(Newsfile Corp. - January 18, 2022) - Bonus BioGroup (TASE: BONS) or "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, submitted results for its multicenter, Phase-II clinical trial to the Israeli Ministry of Health on January 9th. Following on the heels of the Company's initial release of encouraging preliminary results in November 2021, the trial data submitted last week further demonstrate the high levels of efficacy...
2022-01-18 9:00 AM EST -
Bonus BioGroup Reports 94% Survival Rate for Severe COVID-19 Cases in the Phase II Clinical Trial of its MesenCure Treatment
Tel Aviv, Israel--(Newsfile Corp. - December 2, 2021) - Bonus BioGroup or (TASE: BONS) "the Company", a clinical-stage Israeli biotechnology company engaged in the research and development of biomedical tissue-engineered and cell therapy products, has announced results of phase II clinical trial for MesenCure, the Company's treatment for severe COVID-19. The positive results reported by the Company coincide with the emergence of the highly-mutated Omicron variant that has regalvanized the international community's commitment to developing long-term solutions for the ongoing...
2021-12-02 2:00 AM EST
